Iovance Biotherapeutics, Inc. Profile Avatar - Palmy Investing

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinica…

Biotechnology
US, San Carlos [HQ]

Risk Factors

By Management
10-K
  1. We may rely on third parties to perform many essential services for any products that we commercialize, including services related to distribution, government price reporting, customer service, accounts receivable management, cash collection, and adverse event reporting. If these third parties fail to perform as expected or to comply with legal and regulatory requirements, our ability to commercialize our current or future products will be significantly impacted and we may be subject to regulatory sanctions.

  2. We may need additional financing to fund our operations and complete the development of our various product candidates and commercialization of our products, and if we are unable to obtain such financing, we may be unable to complete the development of our product candidates and commercialization of our products. Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

  3. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results. As a result, we could become subject to sanctions or investigations by regulatory authorities and/or stockholder litigation, which could harm our business and have an adverse effect on our stock price.

Get PRO Today.

Read 22 more risk factors of Iovance Biotherapeutics, Inc.

End of IOVA's Analysis
CIK: 1425205 CUSIP: 462260100 ISIN: US4622601007 LEI: - UEI: -
Secondary Listings
IOVA has no secondary listings inside our databases.